ID   OV-90
AC   CVCL_3768
SY   OV90
DR   BTO; BTO_0004852
DR   CLO; CLO_0008276
DR   EFO; EFO_0002311
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-3585
DR   ATCC; CRL-11732
DR   BioGRID_ORCS_Cell_line; 393
DR   BioSample; SAMN03471308
DR   BioSample; SAMN10987765
DR   cancercelllines; CVCL_3768
DR   CancerTools; 161765
DR   Cell_Model_Passport; SIDM01141
DR   ChEMBL-Cells; CHEMBL4295466
DR   ChEMBL-Targets; CHEMBL4296481
DR   Cosmic; 1102815
DR   Cosmic; 1113283
DR   Cosmic; 1139219
DR   Cosmic; 1305311
DR   Cosmic; 1709257
DR   Cosmic; 2186586
DR   Cosmic-CLP; 1240197
DR   DepMap; ACH-000291
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1240197
DR   GEO; GSM274704
DR   GEO; GSM659389
DR   GEO; GSM711702
DR   GEO; GSM784576
DR   GEO; GSM851926
DR   GEO; GSM887483
DR   GEO; GSM888564
DR   GEO; GSM1001427
DR   GEO; GSM1001428
DR   GEO; GSM1001492
DR   GEO; GSM1291148
DR   GEO; GSM1374800
DR   GEO; GSM1670314
DR   GEO; GSM2474988
DR   IARC_TP53; 20198
DR   IGRhCellID; OV90
DR   LiGeA; CCLE_009
DR   LINCS_LDP; LCL-1523
DR   PharmacoDB; OV90_1210_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3768
DR   PubChem_Cell_line; CVCL_3768
DR   Wikidata; Q54936833
RX   Patent=US5710038;
RX   PubMed=10949993;
RX   PubMed=11641787;
RX   PubMed=20204287;
RX   PubMed=20215515;
RX   PubMed=22141344;
RX   PubMed=22328975;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22710073;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=24675677;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27235858;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11732.
CC   Population: Caucasian.
CC   Doubling time: 1.5 days (PubMed=10949993); 40 hours (PubMed=25984343); 46.34 hours (JWGray panel).
CC   HLA typing: A*02:05,02:05; B*15:05,50:01; C*06:02,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1790; CDKN2D + HGNC; HGNC:20482; WDFY2; Name(s)=CDKN2D-WDFY2 (PubMed=24675677).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (DepMap=ACH-000291).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (PubMed=10949993; PubMed=20204287; PubMed=24023729; PubMed=25230021; PubMed=28273451; DepMap=ACH-000291).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Phenotyping; shRNA library screening.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=2.24%; Native American=0%; East Asian, North=2.36%; East Asian, South=0%; South Asian=5.06%; European, North=37.26%; European, South=53.08% (PubMed=30894373).
CC   Misspelling: TOV-90; Cosmic=1139219.
CC   Discontinued: ATCC; CRL-11732; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC=CRL-3585; Cosmic-CLP=1240197; Direct_author_submission; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 12
ST   D21S11: 30,30.2
ST   D3S1358: 18
ST   D5S818: 11,15
ST   D7S820: 10 (Cosmic-CLP=1240197; Direct_author_submission)
ST   D7S820: 10,10.1 (ATCC=CRL-3585; PubMed=25230021; PubMed=25877200)
ST   D7S820: 10.1 (PubMed=30485824)
ST   D8S1179: 12,14
ST   FGA: 21,22
ST   Penta D: 12,13
ST   Penta E: 11,13
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 47
//
RX   Patent=US5710038;
RA   Mes-Masson A.-M., Provencher D.M.;
RT   "Primary cultures of normal and tumoral human ovarian epithelium.";
RL   Patent number US5710038, 20-Jan-1998.
//
RX   PubMed=10949993; DOI=10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2;
RA   Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N.,
RA   Wang J.-C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.-M.;
RT   "Characterization of four novel epithelial ovarian cancer cell
RT   lines.";
RL   In Vitro Cell. Dev. Biol. Anim. 36:357-361(2000).
//
RX   PubMed=11641787; DOI=10.1038/sj.onc.1204804;
RA   Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J.,
RA   Manderson E.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Microarray analysis of gene expression mirrors the biology of an
RT   ovarian cancer model.";
RL   Oncogene 20:6617-6626(2001).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22141344; DOI=10.1186/1757-2215-4-21; PMCID=PMC3259089;
RA   Sherman-Baust C.A., Becker K.G., Wood W.H. 3rd, Zhang Y.-Q., Morin P.J.;
RT   "Gene expression and pathway analysis of ovarian cancer cells selected
RT   for resistance to cisplatin, paclitaxel, or doxorubicin.";
RL   J. Ovarian Res. 4:21.1-21.11(2011).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:e72162.1-e72162.13(2013).
//
RX   PubMed=24675677; DOI=10.1371/journal.pgen.1004216; PMCID=PMC3967933;
RA   Kannan K., Coarfa C., Rajapakshe K., Hawkins S.M., Matzuk M.M.,
RA   Milosavljevic A., Yen L.-S.;
RT   "CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade
RT   serous ovarian carcinoma.";
RL   PLoS Genet. 10:e1004216.1-e1004216.10(2014).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:e103988.1-e103988.16(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035.1-140035.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//